Lineage Cell Therapeutics (LCTX) EBT Margin Growth (5y) (2015 - 2026)

Lineage Cell Therapeutics (LCTX) EBT Margin Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Lineage Cell Therapeutics 270.61 Mn 212.77 Mn 1.07 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -49,070.00
Mar 31, 2026 -75,019.00
Dec 31, 2025 -38,095.00
Sep 30, 2025 88,029.00
Jun 30, 2025 87,670.00
Mar 31, 2025 118,629.00
Dec 31, 2024 31,698.00
Sep 30, 2024 300,807.00
Jun 30, 2024 360,796.00
Mar 31, 2024 -421,622.00
Dec 31, 2023 575,444.00
Sep 30, 2023 -735,085.00
Jun 30, 2023 2,108.00
Mar 31, 2023 882,659.00
Dec 31, 2022 779,942.00
Sep 30, 2022 -133,253.00
Jun 30, 2022 413,402.00
Mar 31, 2022 -1.54 Mn
Dec 31, 2021 64,570.00
Sep 30, 2021 -242,057.00